Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 455, Issue 1, 2014, Pages 36-43

  Chen, Yiyin ^a   Yang, Xiaomin ^a   Zhao, Lin ^c   Almásy, László ^d   Garamus, Vasil M ^b   Willumeit, Regine ^b   Zou, Aihua ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF MATERIALS RESEARCH   (Germany)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d WIGNER RESEARCH CENTRE FOR PHYSICS   (Hungary)

Author keywords

Cytotoxicity; Docetaxel; Nanostructured lipid carrier; SANS; SAXS

Indexed keywords

ADDITIVES; BIOCOMPATIBILITY; CYTOTOXICITY; DYNAMIC LIGHT SCATTERING; HYDROGELS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ACTIVE PHARMACEUTICAL INGREDIENTS; DOCETAXEL; NANOSTRUCTURED LIPID CARRIER (NLC); NANOSTRUCTURED LIPID CARRIERS; SANS; SAXS; SMALL ANGLE X-RAY SCATTERING; SMALL-ANGLE NEUTRON SCATTERING;

DRUG PRODUCTS;

CREMOPHOR; DOCETAXEL; DRUG CARRIER; POLOXAMER;

ARTICLE; CYTOTOXICITY; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MTT ASSAY; NEUTRON SCATTERING; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84899832308     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2014.04.032     Document Type: Article

References (49)

1. Mudshinge R.S., Deore A.B., Patil S., Bhalgat C.M. Nanoparticles emerging carriers for drug delivery. Saudi Pharm. J. 2011, 19:129.
2. Wang J.J., Liu K.S., Sung K.C., Tsai C.Y., Fang J.Y. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur. J. Pharm. Sci. 2009, 38:138.
3. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161.
4. Ridolfi D.M., Marcato P.D., Justo G.Z., Cordi L., Machado D., Duran N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf. B: Biointerfaces 2010, 93:36.
5. Venkataraman S., Hedrick J.L., Ong Z.Y., Yang C., Ee P.L.R., Hammond P.T., Yang Y.Y. The effects of polymeric nanostructure shape on drug delivery. Adv. Drug Deliv. Rev. 2011, 63:1228.
6. Nayak A.P., Tiyaboonchai W., Patankar S., Madhusudhan B., Souto E.B. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf. B: Biointerfaces 2010, 81:263.
7. Yang C.R., Zhao X.L., Hu H.Y., Li K.X., Sun X., Li L., Chen D.W. Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers. Chem. Pharm. Bull. 2010, 58:656.
8. Kuo Y.C., Chung J.F. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf. B: Biointerfaces 2011, 83:299.
9. Müller R.H. Lipid nanoparticles: recent advances. Adv. Drug Deliv. Rev. 2007, 59:375.
10. Cortes J.E., Pazdur R. Docetacel. J. Clin. Oncol. 1995, 10:2643.
11. Chevallier B., Fumoleau P., Kerbrat P., Dieras V., Roche H., Krakowski I., Azli N., Bayssas M., Lentz M.A., Van G.M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase trial of the Clinical Screening Cooperative Group of European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 1995, 2:314.
12. Fossella F.V., Lee J.S., Shin D.M., Calayag M., Huber M., Perez-Soler R., Murphy W.K., Lippman S., Benner S., Glisson B. Phase study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Clin. Oncol. 1995, 3:645.
13. Kaye S.B., Piccart M., Aapro M., Francis P., Kavanagh J. Phase trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur. J. Cancer 1997, 13:2167.
14. Zhan W., Shi Y., Chen Y., Yu S., Hao J., Luo J., Sha X., Fang X. Enhanced antitumor efficiency by paclitaxel-loaded pluronic P123/F127 mixed micelled against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 2010, 3:341.
15. Cho H.J., Yoon H.Y., Koo H., Ko S.H., Shim J.S., Lee J.H., Kim K., Kwon I.C., Kim D.D. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32:7181.
16. Zhigaltsev I.V., Winters G., Srinivasulu M., Crawford J., Wong M., Amankwa L., Waterhouse D., Masin D., Webb M., Harasym N., Hrller L., Bally M.B., Ciufolini M.A., Cullis P.R., Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J. Control. Release 2010, 144:332.
17. Xu Z.H., Chen L.L., Gu W.W., Gao Y., Lin L.P., Zhang Z.W., Xi Y., Li Y.P. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226.
18. Liu D.H., Liu Z.H., Wang L.L., Zhang C., Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B: Biointerfaces 2011, 85:262.
19. Naik S., Patel D., Surti N., Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J. Supercrit. Fluids 2010, 54:110.
20. Li X., Li X.R., Qian X., Ding Y., Tu Y., Guo R., Hu Y., Jiang X., Liu B. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur. J. Pharm. Biopharm. 2008, 70:726.
21. Hwang H.Y., Kim I.S., Kwon I.C., Kim Y.H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 2008, 128:23.
22. Puri A., Heldman E., Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26:523.
23. Li X., Wang D.K. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J. Pharm. Pharmcol. 2009, 61:1485.
24. Lin X., Gao R., Tang X. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert Opin. Drug Deliv. 2012, 9:767.
25. Zhuang C.Y., Li N., Wang M., Zhang X.N., Pan W.S., Peng J.J., Pan Y.S., Tang T. Preparation and characterization of vinpocetine loaded nanostructured carriers (NLC) for improved oral bioavailability. Int. J. Pharm. 2010, 394:179.
26. Rosta L. Cold neutron research facility at the Budapest Neutron Centre. Appl. Phys. A 2002, 74:292.
27. Gu M., Suresh P.V. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem. Phys. Lipids 2012, 165:454.
28. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. Semin. Original Invest. 2008, 26:57.
29. Janos S., Franco M.M., Carl R.A. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel as in vitro study. J. Natl. Cancer Inst. 1998, 90:300.
30. Copper M.P., Triesscheijn M., Tan I.B., Ruevekamp M.C., Stewart F.A. Photodynamic therapy in the treatment of multiple primary tumors in the head and neck, located to the oral cavity and oropharynx. Clin. Otolaryngol. 2007, 32:185.
31. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590.
32. Carsten O., Oliver K., Müller R.H. Lipase degradation of dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage and crystallinity. Int. J. Pharm. 2002, 237:119.
33. Carsten S., Barbara R.R., Wolfgang G.K. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur. J. Pharm. Biopharm. 2010, 77:350.
34. Date A.A., Vador N., Jagtap A., Nagarsenker M.S. Lipid nanocarriers (Gelupearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology 2011, 22:275120.
35. Fang J.Y., Fang C.L., Liu C.H., Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008, 70:633.
36. Puglia C., Blasi P., Rizza L., Schoubben A., Rossi F., Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and vivo investigation. Int. J. Pharm. 2008, 357:295.
37. Kovacevic A., Savic S., Vuleta G., Müller R.H., Keck C.M. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int. J. Pharm. 2011, 406:163.
38. Patricia S., Samatha C.P. Polymorphism, crystallinity and hydrophilic lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids Surf. B: Biointerfaces 2011, 86:125.
39. Radheshyam T., Kamla P. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int. J. Pharm. 2011, 415:232.
40. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165.
41. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:p.4930.
42. Zheng K., Zou A.H. The effect of polymer-surfactant emulsifiying agent on the formation and stability of α-lipoic acid loaded nanostructured lipid carriers (NLC). Food Hydrocoll. 2013, 32:72.
43. Müller R.H., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161.
44. Müller R.H., Radtke M. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002, 242:121.
45. Müller R.H., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparation. Adv. Drug Deliv. Rev. 2002, 54:131.
46. Mühlen A.Z., Schwarz C. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149.
47. Yang X.M., Zou A.H. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations. Int. J. Pharm. 2013, 450:225.
48. Brandenburg K., Richter W., Koch M.H.J., Meyer H.W., Seydel U. Characterization of the nonlamellar cubic and HII structures of lipid A from Salmonella enterica serovar Minnesota by X-ray diffraction and freeze-fracture electron microscopy. Chem. Phys. Lipids 1998, 91:53.
49. Souto E.B., Müller R.H. Lipid nanoparticles effect on bioavailability and pharmacokinetic changes. Adv. Drug Deliv. Rev. 2011, 197:115.